GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Q2 FY27 Consolidated Net Profit at Rs. 36.60 Crore

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 29 Oct 2026, 01:56 PM IST  ·  BSE ID: 01e53e14-4236-465a-8915-b16ceffd783d
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its quarterly earnings, showing a net profit of Rs. 36.60 Crore, and appointed new joint auditors.
🤖 AI Summary
  • Senores Pharmaceuticals reported unaudited consolidated net profit after tax of Rs. 36.60 Crore for Q2 FY27.
  • Total consolidated income for the quarter ended September 30, 2026, was Rs. 201.27 Crore.
  • The Board approved M/s Talati and Talati LLP as Joint Statutory Auditors for the period from 2026-27 to 2030-31.
  • Half-year ended September 30, 2026, consolidated net profit after tax stood at Rs. 67.05 Crore.
  • Half-year consolidated total income for FY27 was Rs. 384.29 Crore.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Net Profit after tax (Q2 FY27)
Rs. 36.60 Crore
21.51%
Consolidated Total Income (Q2 FY27)
Rs. 201.27 Crore
20.40%
Consolidated Net Profit after tax (H1 FY27)
Rs. 67.05 Crore
30.73%
Consolidated Total Income (H1 FY27)
Rs. 384.29 Crore
24.56%
🏢 How This Affects the Company
💰
Financial Impact
Consolidated Net Profit After Tax for Q2 FY27 is Rs. 36.60 Crore. Half-year consolidated Net Profit After Tax for FY27 reached Rs. 67.05 Crore.
⚙️
Operational Impact
The appointment of M/s Talati and Talati LLP as Joint Statutory Auditors expands the external audit oversight for the period from 2026-27 to 2030-31.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the reported consolidated net profit after tax for the quarter and half year ended September 30, 2026.
🔍
Management Signal
The Board's approval of unaudited financial results and the appointment of joint statutory auditors indicates ongoing governance and financial reporting practices.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — review net profit and total income trends.
Annual General Meeting — check for any further auditor-related updates.
Operational announcements — observe any new business developments or expansions.
LOW RISK The filing reports routine quarterly financial results and auditor appointments, presenting no unusual risks.
💡 Investor Takeaway
Senores Pharmaceuticals reported unaudited consolidated net profit after tax of Rs. 36.60 Crore for Q2 FY27, up 21.51% YoY from Rs. 30.12 Crore in Q2 FY26. Half-year consolidated net profit after tax was Rs. 67.05 Crore, up 30.73% from Rs. 51.29 Crore in H1 FY26. Consolidated total income for H1 FY27 reached Rs. 384.29 Crore.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Net Profit After Tax for the quarter ended September 30, 2026, was Rs. 36.60 Crore.
  • Consolidated Total Income for the half year ended September 30, 2026, increased to Rs. 384.29 Crore from Rs. 308.51 Crore in the prior comparable period.

⚠️ Concerns

  • Trade Receivables on the consolidated balance sheet decreased to Rs. 253.23 Crore as of September 30, 2026, from Rs. 324.82 Crore as of March 31, 2026.
  • Cash and cash equivalents on the consolidated balance sheet decreased to Rs. 17.96 Crore as of September 30, 2026, from Rs. 45.55 Crore as of March 31, 2026.
📅 Company Track Record
Senores Pharmaceuticals reported Q1 FY27 consolidated Net Profit after tax rose 43.77% YoY to Rs. 30.45 Crore. FY26 Total Income was up 65% to Rs. 664 Crs. with PAT up 108%.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Senores Pharmaceuticals' consolidated net profit for Q2 FY27?
Senores Pharmaceuticals reported an unaudited consolidated net profit after tax of Rs. 36.60 Crore for the quarter ended September 30, 2026.
What was Senores Pharmaceuticals' total consolidated income for Q2 FY27?
The total unaudited consolidated income for Senores Pharmaceuticals for the quarter ended September 30, 2026, was Rs. 201.27 Crore.
What was Senores Pharmaceuticals' consolidated net profit for the half year ended September 30, 2026?
For the half year ended September 30, 2026, Senores Pharmaceuticals' unaudited consolidated net profit after tax was Rs. 67.05 Crore.
Which firm was appointed as Joint Statutory Auditors for Senores Pharmaceuticals?
M/s Talati and Talati LLP, Chartered Accountants (Firm Registration No. 110758W / W100377), have been approved as Joint Statutory Auditors for Senores Pharmaceuticals for the period from 2026-27 to 2030-31.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.